A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)

计划入组 114 人 · 首次发布于 2014 年 12 月 23 日

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

计划入组 92 人 · 首次发布于 2024 年 7 月 18 日

An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)

计划入组 58 人 · 首次发布于 2014 年 10 月 30 日

Garetosmab(Pasatru)

Palovarotene

C₂₇H₃₀N₂O₂

Progressive MS(CuroNZ)

CENTER FOR PROGRESSIVE RECOVERY

United States

CENTER FOR PROGRESSIVE RECOVERY, LLC

United States

FDA Grants Priority Review to Garetosmab for Ultra-Rare Bone Disease Fibrodysplasia Ossificans Progressiva

āshibio Doses First Patient in Phase 2/3 Trial of Andecaliximab for Fibrodysplasia Ossificans Progressiva

Regeneron's Garetosmab Achieves 90% Reduction in Bone Formation in Rare Disease Trial